Tag: WizMediBio
WizMediBio Signs Contract with the Wisconsin Alumni Research Foundation (WARF) for Botulinum Toxin Strain
SEOUL, S.KOREA, Apr 9, 2024 – (ACN Newswire) – WizMedi Bio Co., Ltd. (WizMedi Bio) today announced that it has reached a formal agreement with the Wisconsin Alumni Research Foundation (WARF), established by the University of Wisconsin, for the patent and technical licensing of the A6 botulinum neurotoxin strain. This agreement enables WizMedi Bio to prove the origin of the strain, which has been the primary hurdle to the botulinum toxin business, and paves a pathway to develop a stable new business in the market. The A1 botulinum toxin currently dominates the market and as a novel subtype, A6 presents itself ... Read more